| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3978686 | Bulletin du Cancer | 2012 | 5 Pages |
Abstract
In castrate-refractory prostate cancers, main efficacy endpoints are progression free survival for phase-II trials and overall survival for phase-III trials. However, various progression criteria have been used, and overall survival may become more difficult to impact due to the recent approval of more effective drugs. PSA is useful in clinical practice, provided it is interpreted with caution, but cannot be used as a surrogate endpoint in clinical trials. Finally, circulating tumor cells represent a promising area of development.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Pascal Piedbois, Marc Buyse,